These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36952005)

  • 21. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
    Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
    Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial.
    Shi C; Li Y; Geng L; Shen W; Sui C; Dai B; Lu J; Pan M; Yang J
    Eur J Cancer; 2022 May; 166():176-184. PubMed ID: 35303509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
    Chen YH; Chen YY; Wang JH; Hung CH
    Anticancer Res; 2023 Mar; 43(3):1377-1384. PubMed ID: 36854513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.
    Su K; Guo L; Ma W; Wang J; Xie Y; Rao M; Zhang J; Li X; Wen L; Li B; Yang X; Song Y; Huang W; Chi H; Gu T; Xu K; Liu Y; Chen J; Wu Z; Jiang Y; Li H; Zeng H; Wang P; Feng X; Chen S; Yang B; Jin H; He K; Han Y
    Front Immunol; 2022; 13():972503. PubMed ID: 36211350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
    Jun BG; Kim SG; Kim YD; Cheon GJ; Han KH; Yoo JJ; Kim YS; Jeong SW; Jang JY; Lee SH; Park S; Kim HS
    PLoS One; 2018; 13(10):e0206381. PubMed ID: 30379885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.
    Bettinger D; Gkika E; Schultheiss M; Glaser N; Lange S; Maruschke L; Buettner N; Kirste S; Nestle U; Grosu AL; Thimme R; Brunner TB
    BMC Cancer; 2018 Aug; 18(1):807. PubMed ID: 30092781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of Lenvatinib and Proton Beam Therapy in the Management of Patients With Advanced Hepatocellular Carcinoma.
    Cheng JY; Huang BS; Chen YY; Wang CC; Chen YH
    Anticancer Res; 2023 Mar; 43(3):1361-1371. PubMed ID: 36854503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score-Matched Analysis.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    J Hepatocell Carcinoma; 2022; 9():685-694. PubMed ID: 35937909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Yuan W; Yue W; Wen H; Wang X; Wang Q
    Eur Surg Res; 2023; 64(2):268-277. PubMed ID: 36812900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.
    Wang M; Zhou Q; Li H; Liu M; Li R; Wang W; Wang X; Huang J; Duan F
    Immunotargets Ther; 2024; 13():447-459. PubMed ID: 39280092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis.
    Wang XH; Liu CJ; Wen HQ; Duan XH; Jiao YQ; Liu YJ; Chen MS; Zhu KS; Mao XH; Zhou QF
    Clin Transl Med; 2023 Mar; 13(3):e1214. PubMed ID: 36855781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
    Wei F; Huang Q; He J; Luo L; Zeng Y
    Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion.
    Munoz-Schuffenegger P; Barry A; Atenafu EG; Kim J; Brierley J; Ringash J; Brade A; Dinniwell R; Wong RKS; Cho C; Kim TK; Sapisochin G; Dawson LA
    Radiother Oncol; 2021 Mar; 156():120-126. PubMed ID: 33285195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study.
    Guo P; Pi X; Gao F; Li Q; Li D; Feng W; Cao W
    Front Oncol; 2022; 12():945915. PubMed ID: 36338683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
    Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis.
    Jung J; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Kim JH
    BMC Cancer; 2015 Dec; 15():987. PubMed ID: 26681337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Chiang CL; Chiu KW; Lee FA; Kong FS; Chan AC
    Front Oncol; 2021; 11():798832. PubMed ID: 34950594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
    Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.